STOCK TITAN

Baxter International Inc. - BAX STOCK NEWS

Welcome to our dedicated news page for Baxter International (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter International.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Baxter International's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Baxter International's position in the market.

News
Rhea-AI Summary
Baxter International Inc. (BAX) declares a quarterly cash dividend of $0.29 per share, with an annual rate of $1.16, payable on April 1, 2024, to stockholders of record as of March 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
dividends
-
Rhea-AI Summary
Baxter International Inc. reported a 4% increase in fourth-quarter sales, reaching $3.89 billion. Full-year sales grew by 2% to $14.81 billion. The company's U.S. GAAP diluted EPS from continuing operations was $0.14 for the fourth quarter and ($0.15) for the full year. Adjusted diluted EPS from continuing operations was $0.88 for the fourth quarter and $2.60 for the full year. Baxter is preparing for the proposed separation of its Kidney Care segment into a standalone company named Vantive. The company reported strong sales growth in the Healthcare Systems and Technologies segment, while Kidney Care sales declined. Baxter also highlighted key strategic priorities and corporate responsibility initiatives for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
earnings
-
Rhea-AI Summary
Baxter International Inc. (BAX) will host a conference call to discuss its fourth-quarter 2023 financial results on February 8, 2024, at 7:30 a.m. Central Time. Participants can pre-register for the call and access the webcast through Baxter's website. The call will be recorded and is copyrighted material.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences earnings
Rhea-AI Summary
Baxter International Inc. (NYSE:BAX) has successfully completed the first phase of its intravenous (IV) bag recycling program pilot in collaboration with Northwestern Memorial Hospital, diverting more than six tons of polyvinyl chloride (PVC) IV bag waste from landfills. This innovative program demonstrates Baxter's commitment to corporate responsibility and waste reduction, with plans to expand the program to support scalability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
none
-
Rhea-AI Summary
Baxter International Inc. (BAX) to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. José (Joe) E. Almeida, Chairman, President, and CEO, will present at 10:30 a.m. Pacific Time. The live webcast can be accessed at www.baxter.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
conferences
-
Rhea-AI Summary
Baxter International Inc. (NYSE:BAX) published its first report aligned with the Task Force on Climate-related Financial Disclosures (TCFD) recommendations, showcasing the company's commitment to transparency and strong disclosure in managing climate-related risks and opportunities. The report is designed to improve climate-related disclosure relevant to investors and key stakeholders, as Baxter continues to make a positive impact on patients, the planet, and communities. Baxter has been named to the Dow Jones Sustainability Index (DJSI) North America for 2023, marking its continuous inclusion in DJSI North America since 2005.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
none
Rhea-AI Summary
Baxter International Inc. (BAX) partners with UNICEF to improve access to safe drinking water and sanitation in Egypt with a $2.5 million grant. This three-year initiative aims to implement climate-smart water, sanitation, and hygiene (WASH) programming for thousands of people in Upper Egypt’s governorates of Aswan, Assiut, Quena, Minya, and Luxor through community engagement, education, and rehabilitation of primary health units.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
partnership
-
News
Rhea-AI Summary
Baxter International Inc. (NYSE:BAX) Declares Quarterly Dividend of $0.29 per Share, Payable on January 2, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
dividends
-
Rhea-AI Summary
Baxter International Inc. announces new data indicating that its Sharesource remote patient management platform is associated with a 77% reduction in risk of peritoneal dialysis technique failure. Additionally, the HDx therapy enabled by Theranova dialyzer can help reduce water consumption by 27% and electricity usage by 17% compared to hemodiafiltration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
Rhea-AI Summary
Baxter International Inc. reported third-quarter revenue of $3.71 billion, a 3% increase on a reported basis and 2% increase on a constant currency basis. The company's adjusted EPS from continuing operations was $0.68, exceeding guidance. Baxter has implemented a new operating model with four verticalized business segments. The company completed the divestiture of its BioPharma Solutions business and is progressing with the planned spinoff of its Kidney Care segment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.45%
Tags
earnings
Baxter International Inc.

NYSE:BAX

BAX Rankings

BAX Stock Data

21.21B
505.79M
0.26%
92.63%
1.47%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Deerfield

About BAX

baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.